Evidence map›Paper›PMID 31935717›Full record

ArticleJournal of innate immunity2020

SERINC5 Is an Unconventional HIV Restriction Factor That Is Upregulated during Myeloid Cell Differentiation.

Ariane Zutz, Christian Schölz, Stephanie Schneider, Virginia Pierini, Maximilian Münchhoff, Kathrin Sutter, Georg Wittmann, Ulf Dittmer, Rika Draenert, Johannes R Bogner and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of innate immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. SERINC4 is dispensable for male fertility and spermatogenesis in mice.American journal of translational research · 2025
    Article
  3. Review
  4. Review
  5. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  6. HIV-1 restriction by SERINC5.Medical microbiology and immunology · 2023
    Review
  7. Review
  8. Review
  9. Early treatment with anti-αFrontiers in immunology · 2022
    Article
  10. CoelacanthJournal of virology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ariane ZutzMax von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
Christian SchölzMax von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany, schoelz@mvp.lmu.de.
Stephanie SchneiderMax von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
Virginia PieriniCenter for Infectious Diseases, Integrative Virology, University of Heidelberg, Heidelberg, Germany.
Maximilian MünchhoffMax von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
Kathrin SutterInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Georg WittmannDepartment of Transfusion Medicine, Cell Therapeutics, and Hemostaseology, Department of Anesthesiology, University Hospital Munich, Munich, Germany.
Ulf DittmerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Rika DraenertDivision of Infectious Diseases, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
Johannes R BognerDivision of Infectious Diseases, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
Oliver T FacklerCenter for Infectious Diseases, Integrative Virology, University of Heidelberg, Heidelberg, Germany.
Oliver T KepplerMax von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany.
Ludwig-Maximilians-Universität München · DEGerman Center for Infection Research · DEHeidelberg University · DEUniversity of Duisburg-Essen · DELMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classical antiviral restriction factors promote cellular immunity by their ability to interfere with virus replication and induction of their expression by proinflammatory cytokines such as interferons. The serine incorporator proteins SERINC3 and SERINC5 potently reduce the infectivity of HIV-1 particles when overexpressed, and RNA interference or knockout approaches in T cells have indicated antiviral activity also of the endogenous proteins. Due to lack of reagents for detection of endogenous SERINC proteins, it is still unclear whether SERINC3/5 are expressed to functionally relevant levels in different primary target cells of HIV infection and how the expression levels of these innate immunity factors are regulated. In the current study, analysis of SERINC3/5 mRNA steady-state levels in primary lymphoid and monocyte-derived cells revealed selective induction of their expression upon differentiation of myeloid cells. Contrary to classical antiviral restriction factors, various antiviral α-interferon subtypes and proinflammatory interleukins had no effect on SERINC levels, which were also not dysregulated in CD4+ T cells and monocytes isolated from patients with chronic HIV-1 infection. Notably, HIV-1 particles produced by terminally differentiated monocyte-derived macrophages with high SERINC5 expression, but not by low-expressing monocytes, showed a Nef-dependent infectivity defect. Overall, these findings suggest endogenous expression of SERINC5 to antivirally active levels in macrophages. Our results classify SERINC5 as an unconventional HIV-1 restriction factor whose expression is specifically induced upon differentiation of cells towards the myeloid lineage.

Indexed as

CD4-Positive T-LymphocytesCell DifferentiationCytokinesHIV-1HIV InfectionsHumansImmunity, InnateMacrophagesMembrane GlycoproteinsMembrane ProteinsMonocytesMyeloid Cellsnef Gene Products, Human Immunodeficiency VirusRNA, MessengerVirus ReplicationCytokinesMembrane GlycoproteinsMembrane Proteinsnef Gene Products, Human Immunodeficiency VirusRNA, MessengerSERINC3 protein, humanSERINC5 protein, humanAdaptive immunityHIVInnate restriction factorMyeloid cell differentiationSERINC5

Identifiers

PMID31935717
PMCPMC7900780
OpenAlexW3000039096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.